Reagents and consumables
Ended Awarded Last action
- Contract number
- 75N91021F00011
- Awardee
-
Roche Diagnostics Corporation UEI JDMDFEZBYH36
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $65,195
Award facts
- Contract value 100% obligated
- $65,195.01 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Castleton, IN 46256, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$0 | |
| Original award | $65,195 |
About this award
The National Cancer Institute awarded a delivery order to Roche Diagnostics Corporation for reagents and consumables supporting Ventana Medical Systems Benchmark Ultra immunostainers, with a ceiling value of $65,195.01 and firm fixed-price terms. The award, issued on August 16, 2021, with an ultimate completion date of September 15, 2021, represents administrative de-obligation of unexpended and expiring fiscal year 2021 funding in preparation for the September 30, 2026 closing of the period of availability for those funds. The contract carries no set-aside designation and involves performance at Roche Diagnostics' facility in Castleton, Indiana.
Roche Diagnostics Corporation, a foreign-owned manufacturer headquartered in Indianapolis, is a global leader in in vitro diagnostic solutions with an extensive federal contracting presence across the Department of Veterans Affairs, Defense Health Agency, Centers for Disease Control and Prevention, and National Institutes of Health. The company supplies comprehensive diagnostic equipment, testing systems, and specialized reagents for histology staining, molecular diagnostics, immunochemistry, and point-of-care testing. This delivery order is a child contract supporting Roche's broader portfolio of diagnostic capabilities provided to federal healthcare agencies, including multiple active indefinite delivery contracts and blanket purchase agreements extending through 2030 that collectively value tens of millions of dollars.
Quick answers
Who was awarded contract 75N91021F00011?
75N91021F00011 was awarded to Roche Diagnostics Corporation by National Cancer Institute (National Institutes of Health) on August 16, 2021.
How much is contract 75N91021F00011 worth?
The government has obligated $65,195 on 75N91021F00011.
Is contract 75N91021F00011 an order under another contract?
Yes. 75N91021F00011 is a delivery order under 75N91019D00038, an indefinite delivery contract.
Was contract 75N91021F00011 competed?
The extent of competition for 75N91021F00011 was not competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award